Hospira Recalls Hydromorphone HCl Injection
The company is recalling three lots of Hydromorphone HCl Injection USP CII 10 mg/mL, 1 mL in 2 mL Single Dose Vials because of possibly empty or cracked vials.
Hospira, a Pfizer company, announced on March 5, 2018, that it was voluntarily recalling three lots of Hydromorphone HCl Injection USP CII 10 mg/mL, 1 mL in 2 mL Single Dose Vials to the hospital level. The recall was initiated on Feb. 7, 2018 because some units might have empty or cracked vials. Hydromorphone HCl, an opioid agonist, is used to manage severe pain.
According to the company, cracked vials might lead to a compromise in sterility, which may cause bloodstream infections. In addition to sterility concerns, the cracked vials could result in injury to healthcare professions. As of March 5, Hospira has not received any reports of adverse events associated with the recalled product.
The affected lots have expiration dates of November 1, 2018, September 1, 2018, and October 1, 2018 and were distributed nationwide. The company is advising distributers and hospitals to stop use and distribution of the recalled lots. Adverse events may be reported to FDA’s MedWatch program.
Source: FDA
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
